pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioSpace·1h ago·1 min read
save

Alzheimer’s field looks beyond amyloid as biopharma converges at CTAD 2026

Nov 16, 2026·read at BioSpace ↗

This week, biopharma companies including Biogen, Bristol Myers Squibb and Roche are in Boston with new data on their efforts to tackle Alzheimer’s disease.

source

Reporting by BioSpace.

read at BioSpace ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 39m agoEmerging biotech hubs step up as innovation economics evolveBioSpace
  • 40m agoBioSpace 40 Under 40 winners Paull, Zhang let patients with rare disease lead the way at BridgeBioBioSpace
  • 1h agoDeaths, failed trials and other recent setbacks in the autoimmune spaceBioSpace
  • 4h agoCellectis may cut 70% of workforceBioSpace
  • 16h agoSummit's PD-1xVEGF rejected by FDA in lung cancerBioSpace